Nuvalent, Inc.
This page provides a comprehensive, data-driven snapshot of the Nuvalent, Inc. share listed on the NMS exchange. The data presented here is real and not based on assumptions. Since the data is refreshed on a daily or weekly basis, there may be a slight delay. On this page, you can view metrics such as market cap, day's high/low, 52-week high/low, the stock's P/E ratio, and other factors, and compare them with other stocks. While we do not claim that this data alone should dictate your financial decisions, it can certainly assist you in making them; the date of the last data refresh is displayed below the stock price. Explore Nuvalent, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
NUVL — Monthly Price History
Adjusted close price · Hover to see price & month
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Vertex Pharmaceuticals Incorporated | $451.63 | 26.79 | $114.63 B | — | — | 0.24% | $507.92 / $362.5 | $76.18 |
| 2. | Regeneron Pharmaceuticals, Inc. | $810.31 | 19.69 | $85.22 B | 0.44% | 10.23% | 13.81% | $859.34 / $541 | $295.71 |
| 3. | Moderna, Inc. | $140.33 | — | $58.11 B | — | -29.7% | -39.2% | $176.66 / $22.28 | $21.95 |
| 4. | Revolution Medicines, Inc. | $207.32 | — | $45.01 B | — | -57.28% | -54.06% | $224.31 / $39.17 | $8.28 |
| 5. | Royalty Pharma plc | $60.59 | 45.13 | $36.78 B | 2.96% | 8.21% | 12.25% | $64.38 / $34.08 | $11.22 |
| 6. | Alnylam Pharmaceuticals, Inc. | $260.1 | 44.07 | $35.61 B | — | 14.33% | 93.61% | $495.55 / $197.81 | $5.96 |
| 7. | Roivant Sciences Ltd. | $41.48 | — | $34.19 B | — | -21.06% | -6.12% | $37.97 / $12.54 | $6.28 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -102.23 M | -112.7 M | -104.57 M | -94.81 M | -86.3 M | — |
| Net Profit | -118.7 M | -122.44 M | -99.65 M | -84.58 M | -74.76 M | — |
| EPS in Rs | -1.62 | -1.67 | -1.36 | -1.16 | -1.02 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -414.31 M | -280.37 M | -149.49 M | -86.11 M |
| Net Profit | -425.38 M | -260.76 M | -126.22 M | -81.85 M |
| EPS in Rs | -5.81 | -3.56 | -1.72 | -1.12 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.41 B | 1.14 B | 732.38 M | 482.46 M |
| Total Liabilities | 164.37 M | 71.96 M | 31.82 M | 19.48 M |
| Equity | 1.25 B | 1.07 B | 700.56 M | 462.98 M |
| Current Assets | 1.39 B | 1.13 B | 726.49 M | 477.99 M |
| Current Liabilities | 91.17 M | 54.02 M | 31.82 M | 19.48 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -275.21 M | -185.06 M | -99.74 M | -64.97 M |
| Investing CF | -124.08 M | -573.51 M | -143.53 M | -10.66 M |
| Financing CF | 515.34 M | 568.88 M | 336.85 M | 248.92 M |
| Free CF | -275.21 M | -185.06 M | -99.74 M | -64.97 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 years of annual financial statement data.
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -106.59% | -54.2% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend payments and stock split events.
Dividend History
No dividend history available.
Stock Splits
No stock split history available.